Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-05
2010-06-08
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S350000, C546S200000, C546S268100, C548S131000, C548S247000, C548S579000, C549S059000
Reexamination Certificate
active
07732453
ABSTRACT:
The present invention discloses pyrido[2,3-B]pyrazin-3(4h)-ones for use as inhibitors of stearoyl-CoA desaturase. The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, oily skin conditions, metabolic syndrome, and the like.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 4326525 (1982-04-01), Swanson et al.
patent: 4992445 (1991-02-01), Lawter et al.
patent: 5001139 (1991-03-01), Lawter et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5616345 (1997-04-01), Geoghegan et al.
patent: 2004/0019210 (2004-01-01), Connolly et al.
patent: 2008/0249100 (2008-10-01), Chisholm et al.
patent: WO 99/50254 (1999-10-01), None
patent: WO 01/19825 (2001-03-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, p. 205.
Dörwald, F. Zaragoza. Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2005, Preface.
Vippagunta, et al. Advanced Drug Delivery Reviews, 48, 2001, p. 18.
Wolff, Manfred E., Ed. Burger's Medicinal Chemistry and Drug Discovery—Fifth Edition, New York: John Wiley & Sons, 1996, vol. 1, pp. 975-976.
Ntambi et al. (20041Prog Lipid Res43, 91-104; (2005).
A. Dobrzyn and J.M. Ntambi,Obes. Rev.6, (2005), 169-174.
Jiang et al. Prevention of Obesity in Mice by Antisense Oligonucleotide Inhibitors of Stearoyl-CoA Desaturase—1 (2005)J. Clin. Invest. 115:1030-1038.
Gutiérrez-Juárez et al. Critical Role of Stearoyl-CoA Desaturase—1 (SCD1) In the Onset of Diet-Induced Hepatic Insulin Resistance (2006)J. Clin. Invest.116:1686-1695.
Talamo and Bloch (1969)Analytical Biochemistry29:300-304.
Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, PA 17thEd. (1985).
Chisholm, et al.,The LXR Ligand T0901317 Induces Severe Lipogenesis in the db/db Diabetic Mouse; J Lipid Res., vol. 44, No. 11, 2003; 2039-2048.
Glushkov Andrey
Ivanov Alexey
Koltun Dmitry
Parkhill Eric
Vasilevich Natalya
Gilead Palo Alto, Inc.
Hartrum J. Elin
Willis Douglas M
Wilson James O
LandOfFree
Pyrido[2,3-B] pyrazin-3(4H)-ones for use as stearoyl CoA... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrido[2,3-B] pyrazin-3(4H)-ones for use as stearoyl CoA..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrido[2,3-B] pyrazin-3(4H)-ones for use as stearoyl CoA... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4203063